Nice post, georgejjl - ANAVEX 1066, or its metabolites, or isomers, or salts, for use in treating symptoms of, or preventing an infection by a coronavirus, particularly an infection caused by a SARS-CoV-2 virus. Keep them coming..👍️
Yawn. You can’t charge $300K-$500K a year for a prevention or treatment of SARS-CoV-2 virus. The vaccines work and they’re cheap and Paxlovid works and most health insurance policies cover the cost.
Missling is wasting his time with this nonsense. This has absolutely no effect on shareholder value. Missling should be focused on getting Blarcamesine approved and stop with useless patents.